Abstract
This review article assesses the currently available data on new drugs used on and off license for overactive bladder, highlighting the range of pharmacological options. The drugs being considered are solifenacin, darifenacin, transdermal oxybutynin, modified-release propiverine, intravesical botulinum toxin, duloxetine and desmopressin. Although these agents encompass several different modes of action, there is still little evidence to help decide which agent might suit which patient. Furthermore, there have been limited head-to-head studies comparing the efficacy and tolerability of newer drugs. The article concludes with a speculative 5-year view of future developments in the pharmacology of overactive bladder.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
